Ticker brief
OCUL OCULAR THERAPEUTIX INC
Consumer, Non-cyclical · Pharmaceuticals
last close
$6.50
1 day
-1.7%
14 days
-13.8%
mkt cap
$2.1B
signals 14d
12
authors 14d
3
crowd 14d
-2.3σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 103% mid · 61 pctile own 1y | IV/HV 1.38× (as of 2026-09-30) |
| Skew — 25Δ RR 30d | +0.073 81 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | +0.92 elevated | 5-session Δ +0.25 (as of 2026-07-07) |
| OI alarm | quiet | last alarm 2026-02-25 (z=3.0) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-05 → 2026-10-15 · now +0.70 (−1 bearish … +1 bullish)
Who spoke3
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -1.06 | 10 | +0.37 |
| @Quantumup1 | C | +0.10 | 1 | +0.40 |
| @KampnerSam | A | -1.38 | 1 | -0.56 |
Recent signals12of 12 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @semodough | +0.70 | UBS sees Axpaxli reaching market in about 18 months and generating $3.3B in 2035 sales. | -11.9% | tweet ↗ |
| 2026-10-14 | @KampnerSam | -0.56 | Quantifies severe drawdowns across four eye-care pharmaceutical stocks. | -9.7% | tweet ↗ |
| 2026-10-13 | @semodough | +0.40 | BofA reiterated Buy with a $27 target as Ocular reported supportive Axpaxli analysis and an on-track NDA. | -10.2% | tweet ↗ |
| 2026-10-12 | @semodough | +0.15 | Baird's cross-trial comparison raises doubts that Kodiak's Zenkuda is differentiated. | -14.0% | tweet ↗ |
| 2026-10-12 | @semodough | +0.25 | Baird identifies unresolved durability and retreatment-rule questions for Kodiak versus Axpaxli. | -14.0% | tweet ↗ |
| 2026-10-12 | @semodough | +0.55 | Says OCUL durability appears unmatched while questioning Kodiak's sponsorship advantage. | -14.0% | tweet ↗ |
| 2026-10-12 | @semodough | +0.55 | UBS models $3.3B in 2035 sales and sees Axpaxli unlocking substantial value in a $20B market. | -14.0% | tweet ↗ |
| 2026-10-12 | @Quantumup1 | +0.40 | UBS initiated OCUL at Buy with a $14 target, citing Axpaxli's retinal-therapy opportunity. | -14.0% | tweet ↗ |
| 2026-10-11 | @semodough | +0.35 | Persistent DME in up to 40% of patients is presented as unmet need for new approaches. | -13.8% | tweet ↗ |
| 2026-10-10 | @semodough | +0.10 | Shares OCUL's second industry-showcase slide deck on durable management of nAMD. | -13.8% | tweet ↗ |
| 2026-10-05 | @semodough | +0.25 | Management expects a full NDA filing in Q4 and is preparing for launch and strategic discussions. | -10.3% | tweet ↗ |
| 2026-10-05 | @semodough | +0.40 | Piper sets a $31 OCUL target and highlights Axpaxli filing and launch progress after KOD weakness. | -10.3% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.